Stock Locations

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

1802246-60-1Apremilast Dimer

● In Stock

Catalogue No.:	VL6770011
CAS No.:	1802246-60-1
Mol. Formula:	C30H27N3O9S
Mol. Weight:	605.62 g/mol

Request a quote

Add to RFQ list

Additional information on CAS 1802246-60-1

Parent drug

Apremilast

IUPAC Name

(S)-N-(2′-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1, 1′, 3, 3′-tetraoxo-[2, 4′-biisoindolin]-4-yl)acetamide

Pharmacopoeial Synonyms

N/A

Other Synonyms

N-[2′-[(1S)-1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,1′,3,3′-tetrahydro-1,1′,3,3′-tetraoxo[2,4′-bi-2H-isoindol]-4-yl]acetamide

Smiles

CC(NC1=CC=CC(C(N2C3=CC=CC(C(N4[C@@H](C5=CC=C(OC)C(OCC)=C5)CS(=O)(C)=O)=O)=C3C4=O)=O)=C1C2=O)=O

Inchl

InChI=1S/C30H27N3O9S/c1-5-42-24-14-17(12-13-23(24)41-3)22(15-43(4,39)40)33-28(36)19-9-7-11-21(26(19)30(33)38)32-27(35)18-8-6-10-20(31-16(2)34)25(18)29(32)37/h6-14,22H,5,15H2,1-4H3,(H,31,34)/t22-/m1/s1

Description

Apremilast Dimer is a meticulously characterized reference material that complies with rigorous regulatory requirements, including those defined by USP, EMA, JP, and BP. This product plays a crucial role in Abbreviated New Drug Applications (ANDA), New Drug Applications (NDA), and the commercial manufacturing of Apremilast. It is further supported by a detailed Structure Elucidation Report (SER), ensuring high accuracy and reliability across a broad range of analytical applications. Apremilast Dimer (CAS NO.-1802246-60-1) is an oral phosphodiesterase 4 inhibitor that has an impact on a wide range of inflammatory mediators involved in psoriasis and psoriatic arthritis, this is a novel treatment that focuses on maintaining a balance between pro-inflammatory and anti-inflammatory signals.

References

Schafer, Peter. â€œApremilast Mechanism of Action and Application to Psoriasis and Psoriatic Arthritis.â€ Biochemical Pharmacology, vol. 83, no. 12, June 2012, pp. 1583â€“90, https://doi.org/10.1016/j.bcp.2012.01.001.